Readers' Comments on "Reassessing Smoore: Mistakes, Crisis, and the Way Forward"

Industry Insight by 2FIRSTS
Jan.04.2024
Readers' Comments on "Reassessing Smoore: Mistakes, Crisis, and the Way Forward"
2FIRSTS released an article titled "Reassessing Smoore: Mistakes, Crisis, and the Way Forward", sparking widespread discussion in the e-cigarette industry.

On January 3rd, 2FIRSTS published an in-depth article titled "Rethinking Smoore: Mistakes, crisis, and a way forward". The article immediately sparked widespread discussion within the e-cigarette industry.

 

2FIRSTS has conducted a comprehensive summary of various perspectives on the Smoore issue thus far. The aim is to provide readers with a more comprehensive viewpoint for further contemplation and discussion.

 

Below are the various perspectives: 

 

@migao: 

 

The missed opportunity in the disposable business and the late push with two major clients are closely related. Smoore mainly operates as an OEM business, meaning that no matter how great its technology is, it is in vain if customers do not utilize it. This inherent passivity in Smoore's role explains why it fell behind in the disposable market. Had BAT positioned themselves earlier in the disposable market, Smoore would have naturally kept up. After all, the technology required for disposable products is relatively low, and Smoore already possessed accumulated enough to meet the product demands.

 

Speculating further, it can be said that the tobacco industry in the UK and the US is not as quick to embrace disposables, not because they are unaware of the trend but rather because they are cautious about entering into cutthroat competition. Up until 2022, they may have held on to the hope that disposables would not gain popularity, considering the significant profit gap compared to pod-based systems. However, they eventually realized that they couldn't ignore the trend and had to personally engage in the market. Losing market share is more terrifying than sacrificing profits.

 

Therefore, based on the aforementioned points, it is not surprising that Smoore's lagging behind in the market carries a certain degree of expected sorrow.

 

The game of major client and the demand for optimizing supply chain costs for major clients have been clearly reflected in the past year in British American Tobacco and RELX. This year, British American Tobacco has placed 50% or even more of its disposable business with FirstUnion. Although they have introduced multiple new products this year, the main existing models and a new flagship model are now dominated by FirstUnion. This directly led to Smoore's failure to achieve its target of 4 billion in disposable business at the beginning of the year. If it had not been transferred to FirstUnion, Smoore's disposable business this year would have been around 50-60, but I estimate it will be around 35. RELX also experienced a similar situation, where the domestic market shifted from being solely supplied by Smoore to being shared by Smoore, FirstUnion, and ALD. As for the overseas market, I do not have the data, but I conservatively estimate that Smoore now accounts for less than 40%.

 

@Keepupthegoodwork:

 

The entire article fails to mention Smoore's compliance issues, such as PMTA, which is the fundamental reason why it has not entered the US market. In the European market, disposable companies have violated TPD rules by entering with a large number of products, which is also a significant reason why Smoore has not collaborated with these companies. Therefore, Smoore's current situation is largely due to various policy reasons, not its research and development efforts. Additionally, it should be noted that half of Smoore's research and development investment is allocated to HNB products, not solely disposable products, which the articles have failed to mention.

 

@999Roses:

 

In my impression, this seems to be the most detailed article analyzing Smoore. After reading it several times, I feel both disappointed by the setback of a giant and reassured by glimpses of hope. I am someone who believes in the power of time and believes in the order of the world. The road for e-cigarettes is still very long. The market will eventually move away from prioritizing growth data. At that time, the ultimate winner will be the one with the safest product and sufficient trust. There is a saying in the business world, "Don't compare who has a more glamorous life, but who can live longer." Yes, I believe Smoore is the company that will always be at the table.

 

Anonymous user:

 

Smoore has missed out on the best period of overseas development, which is both a strategic misjudgment and a result of their difficulty in ignoring external regulations. They are a company with long-term plans and have not made any fundamental mistakes in major decisions. However, China and overseas markets are two different playing fields, and therefore require two different approaches. Nevertheless, Smoore has once flourished, but it now appears increasingly quiet in the face of external capital speculation.

 

Anonymous User:

 

Smoore's investment is long-term and represents recognition of the regulatory trends surrounding e-cigarette compliance and the regulation of similar tobacco products. Due to requirements for compliance as a public company, Smoore cannot dramatically increase production orders. Additionally, as the tobacco industry is dominated by a few key players, Smoore must maintain strong relationships with these market leaders. In the short term, the e-cigarette market is not yet in a highly regulated era, so Smoore's second growth phase will not occur just yet. As a technology-driven company, Smoore must focus on iterating and innovating its vaporization technology, controlling factory costs, and betting on its new vaporization technology consumer products becoming popular. However, it is still too early to say whether these strategies will be successful.

 

It is even uncertain whether Smoore will remain standing until the day the mist clears.

 

An User on Xueqiu:

 

The analysis is sound, but it is unclear whether the author intentionally or unintentionally overlooked an important point - the importance of compliance and the impact of strong regulation on competition. RELX and Smoore's success was achieved in an environment without stringent regulation, which proved their capabilities as a manufacturer and brand. However, in the later years, the industry faced strong regulation, which noticeably affected major players like RELX and Smoore. On the other hand, new small and medium-sized manufacturers could take advantage of regulatory loopholes for penetration and development of new products, without facing the same restrictions. As a result, RELX and Smoore found themselves constrained within a very limited space, making the competition unequal. The decline in their market share, apart from not keeping up with e-cigarette consumer trends, can largely be attributed to this unfair competition. However, running fast doesn't guarantee running far. From a regulatory standpoint, e-cigarettes are burdened with "original sin." Therefore, compliance with regulations, legality, and ESG (Environmental, Social, and Governance) initiatives are the basic guarantees for companies to persist in the long run. RELX and Smoore possess much stronger capabilities in these aspects compared to other new players, although this often goes unnoticed.

 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

Turning Point Brands Q3 Modern Oral Net Sales Rise 103% to $74.4 Million as Attributable Profit Falls 81%
Turning Point Brands Q3 Modern Oral Net Sales Rise 103% to $74.4 Million as Attributable Profit Falls 81%
Turning Point Brands (TPB) reported third-quarter 2026 Modern Oral net sales of $74.4 million on November 9, up 102.9% year over year and representing 49.2% of consolidated net sales. Total company net sales rose 27.0% to $151.1 million, while net income attributable to TPB declined 81.4% to $3.93 million. The company is expanding the US retail presence of its FRE and ALP nicotine pouch brands and expects its Modern Oral chain-store footprint to grow by more than 70% during 2026. Selling, general and administrative expenses increased 69.1% to $75.3 million, while PMTA-related expenses reached approximately $3.15 million and manufacturing start-up costs totaled about $593,000. ALP plans to open a branded pop-up in New York City's SoHo neighborhood on November 13, alongside a marketing campaign extending into January 2027. TPB owns 50% of ALP but consolidates the venture in its financial statements.
company
Nov.11
Iowa Sets November 16 Vape Directory Launch: Unlisted Products Face Sales Ban, Manufacturers $1,000 Daily Fines per Product
Iowa Sets November 16 Vape Directory Launch: Unlisted Products Face Sales Ban, Manufacturers $1,000 Daily Fines per Product
Iowa plans to publish its first vapor products directory on November 16, 2026, after which products not listed will be prohibited from sale or offer for sale in the state. The Department of Revenue expects to begin penalty enforcement on December 17, following an initial 21-business-day period focused on compliance education. Under House File 2677, retailers, distributors and wholesalers selling unlisted products face civil penalties of $300 per product per day, while manufacturers face $1,000 per product per day. Eligibility extends to FDA-authorized products and certain products meeting historical marketing and pending PMTA requirements. The directory program resumed after a federal appeals court vacated a preliminary injunction in July 2026.
Regulations
Nov.05
JUUL Purchasers Ask Ninth Circuit to Preserve Antitrust Classes in Case Over Altria’s $12.8 Billion Investment
JUUL Purchasers Ask Ninth Circuit to Preserve Antitrust Classes in Case Over Altria’s $12.8 Billion Investment
Private antitrust litigation stemming from Altria's 2018 $12.8 billion investment for a 35% economic interest in JUUL is advancing before the U.S. Court of Appeals for the Ninth Circuit. Direct purchasers, indirect purchasers and indirect resellers of JUUL products filed answering briefs this week seeking to preserve class certifications granted by a California federal court in February. Altria and JUUL argue that individual consumers and large distributors differ too much in purchasing terms to remain in a single direct-purchaser class, while a separate dispute concerns whether California antitrust law can apply to indirect purchasers across 27 jurisdictions. A September trial has been put on hold during the appeal.
Sep.23
U.S. Judge Stays Helix, NJOY Challenge to FDA PMTA Rule Pending New Rulemaking Court Stays Altria's Helix, NJOY Challenge to PMTA Rule as FDA Prepares New Rulemaking
U.S. Judge Stays Helix, NJOY Challenge to FDA PMTA Rule Pending New Rulemaking Court Stays Altria's Helix, NJOY Challenge to PMTA Rule as FDA Prepares New Rulemaking
A federal judge in Texas on Oct. 8 granted a joint request by the FDA and plaintiffs including Altria subsidiaries Helix Innovations and NJOY to stay litigation challenging the agency's 2021 PMTA rule. The court cited FDA's anticipated rulemaking concerning the regulation at issue. FDA announced on Sept. 28 that it intends to reassess the PMTA framework and could initiate new rulemaking to replace it. The parties must file a joint status report within 45 days and every 45 days thereafter. A motion by three Reynolds American companies to intervene remains pending.
Regulations
Oct.10
EU Commission Clarifies Vaping, Smokeless Nicotine Use in Proposed Cardiovascular Checks
EU Commission Clarifies Vaping, Smokeless Nicotine Use in Proposed Cardiovascular Checks
The European Commission has clarified to 2Firsts that its proposed cardiovascular health checks would assess smoking, vaping and the use of smokeless nicotine products as part of patients’ medical histories. The Commission also said Member States may organise additional checks within their healthcare systems. In the same response, it pointed to JRC research on e-cigarettes, heated tobacco products and nicotine pouches that has fed into the evaluation of EU tobacco legislation.
Nov.09
Product | PIXL Adds 6ml PIXL 5K in UK Alongside 12ml PIXL 8000 as Vape Duty Takes Effect
Product | PIXL Adds 6ml PIXL 5K in UK Alongside 12ml PIXL 8000 as Vape Duty Takes Effect
Vaping brand PIXL has introduced the PIXL 5K reusable prefilled pod device in the UK, featuring a 2ml prefilled pod and a 4ml refill container with a combined e-liquid capacity of 6ml. The device uses 20mg/ml nicotine salt e-liquid and is advertised to deliver up to approximately 5,000 puffs. Available through UK retailers by August 2026, the PIXL 5K sits alongside the existing 12ml PIXL 8000. The UK's Vaping Products Duty took effect on October 1 at £0.22 per millilitre, producing theoretical duty amounts of £1.32 and £2.64 for the two products' respective full refill sets.
product
Oct.10